Association between thiopurine exposure and depression in patients with inflammatory bowel disease and rheumatoid arthritis. (October 2020)

• Record Type: Journal Article
• Authors: Sutton, S Scott; Magagnoli, Joseph; Cummings, Tammy; Hardin, James W; Love, Bryan L
• Is Part Of: Journal of psychopharmacology. Volume 34:Number 10(2020)
• Page Start: 1163
• Page End: 1167
• Publication Date: 2020-10
• Subjects: Rac1 -- thiopurines -- depression -- cohort; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/0269881120908898
• Languages: English
• ISSNs: 0269-8811

Abstract

Background: Ras-related C3 botulinum substrate 1 (Rac1) is a member of the small molecule family Rho guanosine triphosphate (GTP)ases. Recent findings reveal epigenetic downregulation of Rac1 is a mechanism of depression. Aims: The purpose of this study was to evaluate Rac1 as a therapeutic target for depression we examine the association between thiopurines, which inhibit Rac1, and the risk of depression among US veterans. Methods: This study uses data spanning January 2000–May 2019, comparing thiopurine exposure (no exposure, less than one year, 1–2.9 years, 3–5 years, and greater than five years) in two separate cohorts, a rheumatoid arthritis cohort and inflammatory bowel disease cohort. We estimate the hazard of depression using a time dependent cox proportional hazards model. Results: A total of 76, 763 rheumatoid arthritis and 46, 787 inflammatory bowel disease patients met all inclusion criteria. Patients exposed to thiopurines less than one year have a 27% (hazard ratio=1.272; 95% confidence interval=(1.038–1.559)) and 67% (hazard ratio=1.667 95% confidence interval=(1.501–1.850)) higher risk of depression in the rheumatoid arthritis and inflammatory bowel disease cohorts, respectively. In the inflammatory bowel disease cohort, we find the risk of depression is increased for up to five years of thiopurine exposure. Conclusion: These results provide evidence that Rac1 regulation is a viable therapeutic target for depression. Further research into therapeutics targeting Rac1 for the treatment of depression is warranted.